Pharmacological properties of a new anticholinergic agent, 1, 1-dimethyl-5-methoxy-3-(dithien-2-ylmethylene) piperidinium bromide (SA-504).
D000779:Anesthetics, Local; D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects; D002415:Cats; D003864:Depression, Chemical; D005260:Female; D005725:Ganglia, Autonomic / Q000187:drug effects; D005750:Gastric Juice / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007509:Irritants; D008297:Male; D008706:Methemoglobin / Q000032:analysis; D008738:Methyl Ethers / Q000494:pharmacology; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009184:Mydriatics; D010276:Parasympatholytics / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012472:Salivation / Q000187:drug effects; D013276:Stomach Ulcer / Q000139:chemically induced; D013876:Thiophenes / Q000494:pharmacology*
D000779:Anesthetics, Local; D007509:Irritants; D008738:Methyl Ethers; D009184:Mydriatics; D010276:Parasympatholytics; D010880:Piperidines; D013876:Thiophenes; D008706:Methemoglobin